MX2016005869A - Inhibidor de beta-lactamasa cristalina. - Google Patents

Inhibidor de beta-lactamasa cristalina.

Info

Publication number
MX2016005869A
MX2016005869A MX2016005869A MX2016005869A MX2016005869A MX 2016005869 A MX2016005869 A MX 2016005869A MX 2016005869 A MX2016005869 A MX 2016005869A MX 2016005869 A MX2016005869 A MX 2016005869A MX 2016005869 A MX2016005869 A MX 2016005869A
Authority
MX
Mexico
Prior art keywords
lactamase inhibitor
crystalline beta
formula
crystalline
beta
Prior art date
Application number
MX2016005869A
Other languages
English (en)
Inventor
Lamonica Alessandro
Forzatti Marco
Biondi Stefano
Original Assignee
Allecra Therapeutics Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49818360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016005869(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allecra Therapeutics Sas filed Critical Allecra Therapeutics Sas
Publication of MX2016005869A publication Critical patent/MX2016005869A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto cristalino de fórmula (I): (ver Fórmula) El compuesto de la fórmula (I) es un inhibidor ß-Iactamasa y puede administrarse en combinación con un agente antibacteriano para la prevención o el tratamiento de una infección bacteriana.
MX2016005869A 2013-11-08 2014-11-07 Inhibidor de beta-lactamasa cristalina. MX2016005869A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1319776.9A GB201319776D0 (en) 2013-11-08 2013-11-08 Compound
GBGB1408643.3A GB201408643D0 (en) 2013-11-08 2014-05-15 Compound
PCT/EP2014/074108 WO2015067787A1 (en) 2013-11-08 2014-11-07 Crystalline beta-lactamase inhibitor

Publications (1)

Publication Number Publication Date
MX2016005869A true MX2016005869A (es) 2017-01-05

Family

ID=49818360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005869A MX2016005869A (es) 2013-11-08 2014-11-07 Inhibidor de beta-lactamasa cristalina.

Country Status (14)

Country Link
US (2) US20160289245A1 (es)
EP (1) EP3066103A1 (es)
JP (2) JP7045795B2 (es)
KR (1) KR20160081964A (es)
CN (1) CN105873935B (es)
AU (1) AU2014345507B2 (es)
CA (1) CA2929199C (es)
CL (1) CL2016001097A1 (es)
EA (1) EA031348B1 (es)
GB (2) GB201319776D0 (es)
IL (1) IL245386A0 (es)
MX (1) MX2016005869A (es)
PE (1) PE20160890A1 (es)
WO (1) WO2015067787A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
ES2178301T3 (es) * 1997-12-29 2002-12-16 Res Corp Technologies Inc Derivados del acido penicilanico 2-beta-sustituido-6-alquilideno como inhibidores de la beta-lactama.
US7273935B2 (en) * 2003-08-21 2007-09-25 Orchid Chemicals & Pharmaceuticals, Ltd. Process for the preparation of 3-methylcepham derivatives
US7417143B2 (en) * 2004-04-07 2008-08-26 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of Tazobactam in pure form
ES2427122T3 (es) * 2006-07-12 2013-10-28 Allecra Therapeutics Gmbh Derivados de metil penam 2-sustituidos
NZ610247A (en) * 2010-11-25 2014-09-26 Allecra Therapeutics Gmbh Β-lactamase inhibitors and their use
US20150140059A1 (en) * 2012-05-07 2015-05-21 The Regents Of The University Of California Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis
JP2016517888A (ja) * 2013-05-02 2016-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 骨選択的骨形成のオキシステロール骨標的薬剤
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
EP3617217B1 (en) * 2014-12-09 2022-09-07 Warsaw Orthopedic, Inc. Process for the production of oxysterols

Also Published As

Publication number Publication date
AU2014345507B2 (en) 2018-11-22
US20160289245A1 (en) 2016-10-06
CA2929199A1 (en) 2015-05-14
EA201690963A1 (ru) 2016-10-31
CL2016001097A1 (es) 2016-12-02
JP2016535054A (ja) 2016-11-10
US20190071456A1 (en) 2019-03-07
CA2929199C (en) 2023-01-03
WO2015067787A1 (en) 2015-05-14
GB201319776D0 (en) 2013-12-25
US11124526B2 (en) 2021-09-21
JP7045795B2 (ja) 2022-04-01
GB201408643D0 (en) 2014-07-02
AU2014345507A1 (en) 2016-05-19
CN105873935B (zh) 2019-03-19
EP3066103A1 (en) 2016-09-14
EA031348B1 (ru) 2018-12-28
JP2021102642A (ja) 2021-07-15
IL245386A0 (en) 2016-06-30
PE20160890A1 (es) 2016-08-25
CN105873935A (zh) 2016-08-17
JP7346485B2 (ja) 2023-09-19
KR20160081964A (ko) 2016-07-08

Similar Documents

Publication Publication Date Title
NZ713621A (en) Compounds and methods of treating infections
NZ713615A (en) Methods for treating bacterial infections
NZ617104A (en) Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
MX348974B (es) Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
WO2015003816A3 (en) Cystobactamides
MX338610B (es) Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
BR112015013123A2 (pt) inibidores de beta-lactamase
MX363678B (es) Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
MX366948B (es) Nuevo inhibidor de beta-lactamasa y proceso para prepararlo.
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
MX2018010878A (es) Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2013005994A (es) Monobactamas.
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
GB2548277A (en) Antibiofilm compositions
MX2016009248A (es) Compuestos que contienen nitrogeno y su uso como agentes antibacterianos.
MX2016011682A (es) Derivados de polimixina y su uso en terapia de combinacion junto con diferentes antibioticos.
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
NZ628927A (en) Compounds and methods for treating candidiasis and aspergillus infections
MX2017009094A (es) Derivado de polimixina y usos del mismo.
MX364443B (es) Agentes antimicrobianos.